Phenome centre move ends GSK role


hammersmith hospital

The MRC-NIHR Phenome Centre will now be hosted at Imperial College’s Hammersmith Hospital, shown here © Imperial College London

Running costs have forced the national MRC-NIHR Phenome Centre to move from the Harlow labs of pharmaceutical company GlaxoSmithKline (GSK), where it was originally going to be sited. Instead, the centre emerging to exploit the NMR and LC–MS capabilities of the Olympic anti-doping labs is moving to a dedicated facility in Imperial College London’s Hammersmith Hospital. The centre’s initial proposal incorrectly assumed that using the GSK site would incur no space and infrastructure charges.

The move is costing Imperial £1 million and delaying the project by three months, but centre director Jeremy Nicholson, emphasises the new site is a better option. ‘The Olympic testing lab could not have been built without GSK and without that there wouldn’t have been a phenome centre,’ Nicholson adds. ‘We are grateful for that.’

‘We are proud to have played a part in the inception of the centre through the offer we made to provide this space,’ a GSK spokesperson says.


Related Content

Phenome Centre goes for gold

15 February 2013 Premium contentFeature

news image

Andy Extance finds out how British researchers are turning Olympic anti-doping facilities into a world-leading facility

Imperial launches second phenome centre

15 November 2012 News and Analysis

news image

New centre aims to improve diagnoses and inform doctors of the best treatments

Most Read

Computational tool leaves electrides with nowhere to hide

25 February 2015 Research

news image

Electride criteria pave way for new research into these fascinating materials

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent